(Q33995048)

30 July 2017

1 reference

title

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (English)

1 reference

30 July 2017

0 references

0 references

1 reference

A W Zuardi

1

1 reference

30 July 2017

J A S Crippa

2

1 reference

30 July 2017

J E C Hallak

3

1 reference

30 July 2017

F A Moreira

4

1 reference

30 July 2017

F S Guimarães

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

3 April 2006

1 reference

Brazilian Journal of Medical and Biological Research

30 July 2017

published in

1 reference

30 July 2017

volume

39

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

421-429

1 reference

Discovery and characterization of endogenous cannabinoids

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Hypnoticlike effects of cannabidiol in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Antianxiety effect of cannabidiol in the elevated plus-maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Effects of cannabidiol (CBD) on regional cerebral blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

To model a psychiatric disorder in animals: schizophrenia as a reality test

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Modern antipsychotic drugs: a critical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Brain dopamine receptors: a primer on their current status, basic and clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Controlled clinical trial of cannabidiol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Cannabis-associated psychosis with hypomanic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Reduced binocular depth inversion in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2006000400001

10.1590/S0100-879X2006000400001

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference